Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Colorectal Neoplasms 3978Pancreatic Neoplasms 2479Carcinoma, Hepatocellular 2413Stomach Neoplasms 2109Rectal Neoplasms 1676Colonic Neoplasms 1629Esophageal Neoplasms 1312Liver Neoplasms 878Neoplasms 633Breast Neoplasms 596Cholangiocarcinoma 525Gastrointestinal Neoplasms 468Neoplasm Metastasis 456Esophageal Squamous Cell Carcinoma 434Lung Neoplasms 422Biliary Tract Neoplasms 277Prostatic Neoplasms 270Ovarian Neoplasms 235Barrett Esophagus 224Adenocarcinoma Of Esophagus 202Gallbladder Neoplasms 191Head and Neck Neoplasms 185Carcinoma, Non-Small-Cell Lung 185Gastrointestinal Stromal Tumors 180Anus Neoplasms 179Recurrence 168Melanoma 162Adenocarcinoma 156Uterine Cervical Neoplasms 153Bile Duct Neoplasms 153

Interventions

Specimen Handling 1Nivolumab 1ADI PEG20 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Resectable Hepatocellular Carcinoma × Gastrointestinal × Clear all
NCT04856046 2026-04-24

Detection of Plasma DNA Methylation in Peripheral Blood From Patients With Resectable Liver Cancer

Mayo Clinic

Active not recruiting
36 enrolled
Gastrointestinal

Resectable Hepatocellular Carcinoma

NCT04965714 2023-02-16

Nivolumab and ADI-PEG 20 Before Surgery for the Treatment of Resectable Liver Cancer

M.D. Anderson Cancer Center

Phase 2 Withdrawn
Gastrointestinal

Resectable Hepatocellular Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡